Illumina (NASDAQ:ILMN) Insider Scott Davies Sells 615 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $98,400.00. Following the sale, the insider owned 21,568 shares in the company, valued at $3,450,880. This represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Up 0.9%

ILMN opened at $164.40 on Tuesday. Illumina, Inc. has a fifty-two week low of $78.79 and a fifty-two week high of $165.97. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm’s fifty day moving average price is $134.48 and its two-hundred day moving average price is $132.39. The company has a market capitalization of $24.87 billion, a P/E ratio of 29.89, a P/E/G ratio of 2.70 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s revenue was up 4.8% on a year-over-year basis. During the same period last year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on ILMN. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday, May 14th. Royal Bank Of Canada initiated coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Finally, Guggenheim lifted their price target on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $138.38.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Glenmede Trust Co. NA raised its position in shares of Illumina by 6.5% during the 1st quarter. Glenmede Trust Co. NA now owns 2,288 shares of the life sciences company’s stock valued at $282,000 after acquiring an additional 140 shares during the last quarter. Groupama Asset Managment raised its position in shares of Illumina by 3.7% during the 1st quarter. Groupama Asset Managment now owns 9,545 shares of the life sciences company’s stock valued at $1,177,000 after acquiring an additional 340 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Illumina by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after acquiring an additional 29,094 shares during the last quarter. Bull Harbor Capital LLC bought a new stake in shares of Illumina during the 1st quarter valued at $1,413,000. Finally, Arkadios Wealth Advisors grew its position in shares of Illumina by 1.6% during the 1st quarter. Arkadios Wealth Advisors now owns 8,001 shares of the life sciences company’s stock worth $986,000 after buying an additional 124 shares during the period. 89.42% of the stock is owned by institutional investors.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
• Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.